All Episodes

May 30, 2024 21 mins

In Part 2 of our conversation, Scott Ohanesian, QuickSTAT’s senior VP of Commercial Operations, and Mike Sweeney, QuickSTAT's Global Head of Strategy for CGT and Direct to Patient Products discuss the various challenges around the logistics of Cell & Gene Therapy – what to look out for and the importance of being prepared.

We also look forward and consider not only the sector’s growth, but what that growth will mean for supply chain logistics. To understand that future, however, we began by asking Mike Sweeney to provide the context of when gene therapy began – and, importantly, how we got from there to here?

For more information on clinical trial logistics, visit our website at

Mark as Played

Advertise With Us

Popular Podcasts

Dateline NBC
Who Killed JFK?

Who Killed JFK?

Who Killed JFK? For 60 years, we are still asking that question. In commemoration of the 60th anniversary of President John F. Kennedy's tragic assassination, legendary filmmaker Rob Reiner teams up with award-winning journalist Soledad O’Brien to tell the history of America’s greatest murder mystery. They interview CIA officials, medical experts, Pulitzer-prize winning journalists, eyewitnesses and a former Secret Service agent who, in 2023, came forward with groundbreaking new evidence. They dig deep into the layers of the 60-year-old question ‘Who Killed JFK?’, how that question has shaped America, and why it matters that we’re still asking it today.

Las Culturistas with Matt Rogers and Bowen Yang

Las Culturistas with Matt Rogers and Bowen Yang

Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.

Music, radio and podcasts, all free. Listen online or download the iHeart App.


© 2024 iHeartMedia, Inc.